For invasive markers, the APOE-ε4 genotype (for the carriers of the APOE-ε4 allele, brain alterations associated with AD may begin as early as infancy) (Liu et al., 2013; Dean et al., 2014), and amyloid-beta (Aβ) accumulation and neurofibrillary lesions are considered to be most important biomarkers for AD (Murphy and LeVine, 2010). This evidence concerns the gene APOE and Alzheimer disease.